Francis Chris 4
4 · Wave Life Sciences Ltd. · Filed Feb 11, 2026
Research Summary
AI-generated summary of this filing
Wave Life Sciences SVP Chris Francis Sells Shares, Receives RSUs
What Happened
Chris Francis, SVP, Corporate Development & Head of Emerging Areas at Wave Life Sciences (WVE), had three reported transactions: an automatic sale of 1,883 ordinary shares on Feb 9, 2026 for $13.45 each (proceeds $25,326) to cover taxes, plus two awards on Feb 5, 2026 — 38,750 restricted stock units (RSUs) and a derivative award of 232,500 shares (option/award) recorded at $0.00. The awards are grants (no cash paid) and are subject to multi-year vesting schedules.
Key Details
- Transaction dates and prices:
- Feb 5, 2026: Award of 38,750 RSUs @ $0.00 (value recorded $0)
- Feb 5, 2026: Derivative award of 232,500 shares @ $0.00 (value recorded $0)
- Feb 9, 2026: Sale of 1,883 shares @ $13.45 — proceeds $25,326 (tax-withholding sale)
- Shares acquired via awards total 271,250 (38,750 RSUs + 232,500 derivative award).
- Shares owned after the transactions: Not specified in the filing.
- Footnotes of note:
- F1: RSUs vest in four equal annual installments (25% each) on Feb 8, 2027–2030.
- F2: The Feb 9 sale was automatic to cover tax withholding from RSU vesting on Feb 8, 2026.
- F3: The derivative award vests 25% on Feb 8, 2027, then 6.25% quarterly until Feb 8, 2030.
- Filing timeliness: Form 4 filed Feb 11, 2026; with the most recent transaction on Feb 9, this appears to have been filed within the usual two-business-day window.
Context
The sale was a routine, automatic tax-withholding sale tied to RSU vesting, not an independent open-market disposition expressing sentiment. The awards are subject to future vesting; the derivative grant is an option-like award with staggered vesting. Purchases tend to be more informative about insider conviction; this filing primarily documents compensation-related grants and a routine sell-to-cover.
Insider Transaction Report
- Award
Ordinary Shares
[F1]2026-02-05+38,750→ 63,750 total - Sale
Ordinary Shares
[F2]2026-02-09$13.45/sh−1,883$25,326→ 61,867 total - Award
Share Option (right to buy)
[F3]2026-02-05+232,500→ 232,500 totalExercise: $12.75Exp: 2036-02-05→ Ordinary Shares (232,500 underlying)
Footnotes (3)
- [F1]Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 8, 2027 through February 8, 2030.
- [F2]On February 9, 2026, the reporting person sold 1,883 ordinary shares solely to cover taxes associated with the vesting of restricted share units ("RSUs") on February 8, 2026. These sales were made pursuant to a provision in the reporting person's RSU agreement that requires automatic sales of shares to cover tax withholding obligations.
- [F3]The option vests as to 25% of the shares on February 8, 2027, and vests as to an additional 6.25% of the shares quarterly thereafter until February 8, 2030.